Figure 6. ROS decrease GLR-1 transport numbers and alter transport dynamics by acting on or downstream of L-VGCCs. All experimental groups express SEP::mCherry::GLR-1 in the glr-1(ky176) background. A, G, I, 25 s from representative kymographs from each experimental group. Scale bar, 5 µm. B, Quantification of transport events from controls, egl-19(rf), or egl-19(gf) without (–, white bars) or with (+, blue bars) the ctl-2(lf) mutation (n ≥ 15). n.s. = not significant, *p = 0.012, **p = 0.007, ***p = 0.0005, compared with controls lacking the ctl-2(lf) mutation. ††††p < 0.0001, compared with egl-19(gf) alone. C, Instantaneous velocity of anterograde transport events in each group (n ≥ 44 events). n.s. = not significant, *p < 0.05, **p = 0.0035, ***p = 0.0005, ****p < 0.0001, compared with controls lacking the ctl-2(lf) mutation. ††††p < 0.0001, compared with egl-19(gf) alone. D, E, Frequency distribution of instantaneous velocity (binned every 0.2 µm/s) of anterograde transport events for egl-19(gf) single and double mutants (D) as well as egl-19(rf) single and double mutants (E) compared with controls lacking ctl-2(lf). F, Percent of time each GLR-1 vesicle spent stopped for each group (n ≥ 44 events). n.s. = not significant, *p = 0.044, **p ≤ 0.009, ****p < 0.0001, compared with controls lacking ctl-2(lf). ††††p < 0.0001, compared with egl-19(gf) alone. H, Quantification of transport events from controls and egl-19(gf) without (–, white bars) or with (+, blue bars) 50 nm H2O2 treatment (n ≥ 18). n.s. = not significant, *p ≤ 0.038, compared with untreated controls. ††p = 0.007, compared with untreated egl-19(gf). J, Quantification of transport events in controls and ctl-2(lf) with (+, blue bars) and without (–, white bars) 10 µm nemadipine treatment (n > 10). n.s. = not significant, *p < 0.05, compared with untreated controls.